KT-333
Hematologic Malignancies
Phase 1Active
Key Facts
About Kymera Therapeutics
Kymera Therapeutics is advancing a robust pipeline of PROTAC degraders targeting transcription factors, scaffolding proteins, and other previously undruggable proteins across oncology, immunology, and other therapeutic areas. The company has built a proprietary platform combining computational chemistry, structural biology, and proteomics to design selective protein degraders. With multiple programs in clinical development and strategic partnerships with leading pharmaceutical companies, Kymera is positioned as a leader in the emerging protein degradation field.
View full company profileTherapeutic Areas
Other Hematologic Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1905 | Jiangsu Hengrui Medicine | Phase 1 |
| Rituximab biosimilar (IBI301) | Innovent Biologics | Approved |
| Alemtuzumab Biosimilar | CSPC Pharmaceutical Group Limited | Phase 3 |
| Lead CAR-T Program | Arcellx | Phase 1 |
| Undisclosed CAR-T programs | Beam Therapeutics | Discovery/Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| Trichostatin A (TSA) | Vanda Pharmaceuticals | Oncology Program |
| Cord Blood HSC Unit | Global Cord Blood | Approved/Commercial |
| TSC-102-A01 | TScan Therapeutics | Preclinical |
| TSC-102-A03 | TScan Therapeutics | Preclinical |
| LBL-007 | LakeShore Biopharma | Phase 1 |
| CER-T Cell Platform | CERo Therapeutics | Pre-clinical |